Skip to Main Content
Skip Nav Destination

ADCs 24 Years On: A Snapshot of the Landscape

June 14, 2024

Abstract: Antibody–drug conjugate development continues apace, with multiple agents highlighted at the recent American Society of Clinical Oncology 2024 Annual Meeting. TROP2-targeting sacituzumab tirumotecan, in combination with PD-(L)1 blockade, showed promise for non–small cell lung cancer, as did c-Met–targeting telisotuzumab vedotin. Meanwhile, M9140, ABBV-706, and MRG004A—aimed at CEACAM5, SEZ6, and TF, respectively—appeared safe and active, particularly in colorectal cancer, small-cell lung cancer, and pancreatic adenocarcinoma.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal